RNS Number: 9432D

CRISM Therapeutics Corporation

07 April 2025

7 April 2025

CRISM Therapeutics Corporation (AIM:CRTX)

Director Dealing

CRISM Therapeutics Corporation ("CRISM" or the "Company") announces that it has been notified that Non-Executive Director, Gerald Beaney has purchased 20,182 ordinary shares of the Company at a price of 9.88 pence per share.

Following this purchase, Mr Beaney holds 45,182 ordinary shares, which represents approximately 0.14% of the Company's total issued share capital of 32,678,312.

Enquiries:

Company CRISM Therapeutics Corporation	Nomad and Broker S.P. Angel Corporate Finance LLP	<i>Financial PR</i> Buchanan
Andrew Webb, CEO Chris McConville, CSO	Richard Morrison Adam Cowl	Mark Court mark.court@buchanancomms.co.uk Jamie Hooper jamie.hooper@buchanancomms.co.uk
via Buchanan	+44 (0) 20 3470 0470	+44 (0) 20 7466 5000

Dealings by Persons Discharging Managerial Responsibilities

1	Details of the person discharging managerial responsibilities / person closely associated		
a)	Name	Gerald Beaney	
2	Reason for the notification		
a)	Position/status	Non-Executive Director	
b)	Initial notification /Amendment	Initial Notification	
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor		
a)	Name	CRISM Therapeutics Corporation	
b)	LEI	213800XFW6MKVCHHPW88	
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted		
a)	Description of the financial instrument, type	Ordinary shares with no par value	

1	ofinstrument	
	Identification code	ISIN: VGG042401262
b)	Nature of the	Purchase of shares
,	transaction	
c)	Price(s) and volume(s)	
	vorume(s)	Director/PDMR Price Volume
		Gerald Beaney 9.88 20,182
d)	Aggregated information	
	- Aggregated volume	20,182
	- Price	£1,993.98
e)	Date of the transaction	7 April 2025
f)	Place of the transaction	Outside a trading venue

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lseg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFLFVISRIDIIE